The changing role of key stakeholders in pharmaceutical value chain
Posted 30th November 2011 in Articles, General | Register to comment
The role of key stakeholders in pharmaceutical value chain has been in a state of transformation over the last decade. Dinar Kale explores.
The pharmaceutical value chain model depicted in Figure 1 covers a full range of activities that are required to bring a product from…
Read the full articlePublication of clinical trial data: enough of the excuses!
Posted 29th November 2011 in Articles, Conferences, General | Register to comment
How much negative data goes unpublished? Ryan Woodrow set to find out and his surprising results are detailed here.
I attended a MedComms Networking event last summer to listen to the thoughts of Ben Goldacre on the pharmaceutical industry. For those of you who…
Read the full articlePayers and personalised medicine: considerations for success
Posted 28th November 2011 in Articles, General | 2 comments
Andree Bates questions the slow uptake of personalised medicine diagniostic tests – are payers proving to be a barrier in this area?
Gleevec and Herceptin (and their clinical and commercial success), were pioneering drugs in terms of…
Read the full articleOf bow ties and diamonds
Posted 24th November 2011 in Articles, General | Register to comment
Sue Wright discusses approaches to the different types of relationships with different Key Accounts.
Over the years I have had the opportunity to work with a number of consultancy organisations including…
Read the full articleCan pharma grow profit while cutting budget without slashing jobs?
Posted 23rd November 2011 in Articles, General | Register to comment
Andree Bates queries the possibility of increasing profit as budget decreases – without lowering the workforce.
According to FiercePharma, Merck plan to slash its workforce by another 12,000 to 13,000 jobs, as part of a plan to…
Read the full articleListening to patients
Posted 22nd November 2011 in Articles, General | Register to comment
Benoit Arnould highlights the significance of patient-reported outcomes.
The emergence of patient-reported outcomes (PROs) has given patients a stronger voice – but are the main chapters of this evolutionary story…
Read the full articlePatent filings and maintenance cost money
Posted 21st November 2011 in Articles, General | Register to comment
Taffy Williams gives us a lesson on the filing and maintenance of patents.
Name brand pharmaceuticals are created and proprietary to the inventing company for the life time of any patents covering the products. Generic drugs began to…
Read the full articleTunnah’s musings: why pharma can learn from drumming gorillas
Posted 18th November 2011 in Articles, General | Register to comment
This month Paul Tunnah is casting his musing gaze beyond pharma and asking whether we need to start looking beyond our own industry for more inspiration and innovation.
If you take a look at the most successful people you know then you will probably find something they all have in common…
Read the full articleAmit Gupta needs you!
Posted 15th November 2011 in Articles, General, Interviews | Register to comment
Moved by the story of a young entrepreneur with leukaemia, we speak to Seth Godin to find out how Amit Gupta is shaking the world with his online campaign for bone marrow donors.
Last week pharmaphorum heard about the story of Amit Gupta, a young entrepreneur living in San Francisco, who has just discovered that he has acute leukaemia…
Read the full articleNHS and pharma: evidence, value and collaboration
Posted 15th November 2011 in Articles, General | Register to comment
Ashish Rishi investigates the evolving relationship of the NHS and pharma.
As the NHS tries to claw back a £20 billion deficit over the next 4 years, we will see a number of fundamental changes to the way we…
Read the full article